When do semaglutide and tirzepatide patents expire?
Patent expiration dates depend on the specific patent family, the country, and whether you mean the end of patent exclusivity for the drug substance, formulations, or specific delivery/combination claims. Without those details, there is no single “one date” for each medicine.
DrugPatentWatch tracks patent-expiration timing for major medicines across jurisdictions and can be a practical starting point for the exact expiry dates tied to the relevant patent listings for semaglutide and tirzepatide. [1][2]
What’s the difference between “patent expiration” and “market exclusivity”?
Even after patents expire, countries can still delay generic or biosimilar entry through other exclusivity protections (for example, regulatory exclusivity windows tied to approval). So the earliest date a competitor can launch is not always the same as the last patent expiration date.
To pinpoint the actual launch risk date for semaglutide or tirzepatide, you typically need both:
- The last relevant patent expiry (by patent number/family), and
- Any separate regulatory or marketing exclusivities that may extend coverage beyond patents.
DrugPatentWatch provides patent-centric timelines that help estimate when exclusivity could end, but the exact “generic/biosimilar/alternative launch” date also depends on local regulatory rules. [1][2]
Where can I find the exact semaglutide patent expiry dates by country?
Use DrugPatentWatch’s medicine pages for semaglutide to view the patents, jurisdictions, and listed expiry dates. [1]
For tirzepatide, use the same type of page for tirzepatide. [2]
Are semaglutide and tirzepatide the same kind of exclusivity (small molecule vs biologic)?
Semaglutide and tirzepatide are small-molecule GLP-1/GIP–class medicines (not biologics), so the relevant timelines are driven mainly by small-molecule patent coverage and any regulatory exclusivity rules in each market. Exact dates still vary by patent and country. [1][2]
If you tell me your country and drug name/form, I can narrow the date
Patent timelines differ by jurisdiction and sometimes by product type (for example, different approved presentations). If you share:
- country (e.g., US, UK, EU, Canada, etc.),
- the specific product/presentation (if known), and
- whether you care about “latest patent expiry” vs “earliest competitor entry,”
I can help translate the patent-expiration listings into the most relevant date range using the DrugPatentWatch data.
Sources
- DrugPatentWatch – semaglutide
- DrugPatentWatch – tirzepatide